Approximately 80% of Americans think that the cost of prescription drugs is unreasonable, and 73% believe that pharmaceutical companies are making too much profit on their products.
Approximately 80% of Americans think that the cost of prescription drugs is unreasonable, and 73% believe that pharmaceutical companies are making too much profit on their products. Those figures come from the Kaiser Family Foundation's Health Tracking Poll, which sought to measure public perceptions of the cost of prescription drugs, attitudes toward policy makers' actions to address prices, and views of pharmaceutical companies.
The poll found that more than half of Americans are taking at least 1 prescription drug, and a quarter are taking at least 4 prescription drugs. Although most respondents (74%) reported that they can afford their medications, among those who said that they take 4 or more drugs, 35% of uninsured people younger than 65 years said that they had skipped filling a prescription because of cost, and 26% reported cutting pills in half or missing doses to save money. Those who had an income of under $40,000 per year reported the worst compliance.
Most respondents (72%) said that pharmaceutical companies have too much influence in Washington, 77% said that pharma’s profits are a major factor contributing to the high cost of drugs, and just over half had an unfavorable view of pharmaceutical companies.
Opinions on how to address high drug prices were divided along partisan lines; 84% of Democrats believed that Democrats would do the best job of bringing down costs, whereas 78% of Republicans said that their own party would do the best job. A majority of Democrats (57%) favored greater regulation to keep down prescription drug costs, while most Republicans (76%) said that market competition would be most effective.
Despite partisan divides, most respondents said that the government should negotiate lower prices for the Medicare program (92%), encourage generic market entry (87%), require manufacturers to disclose pricing information (86%), limit costs of drugs for indications like cancer (78%), and allow for importation of cheaper drugs from Canada (72%).
With respect to drug importation, more respondents (76%) felt confident that buying imported Canadian drugs would make medicine affordable without sacrificing quality versus buying drugs from Canadian online pharmacies (68%).
More than half of respondents (52%) said that passing legislation to bring down the price of drugs should be a top priority for President Trump and Congress in the coming months. That initiative ranks higher in public’s opinion than passing an infrastructure bill, addressing misuse of opioid drugs, or repealing the Affordable Care Act, and most voters say that a candidate’s stance on a national health plan will be an important factor in upcoming elections.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.